1
|
Talukdar A, Doley R. Identification of poorly immunodepleted phospholipase A 2 (PLA 2) proteins of Bungarus fasciatus venom from Assam, India and evaluation of Indian polyvalent antivenom using third-generation antivenomics. Toxicon 2024; 239:107617. [PMID: 38219916 DOI: 10.1016/j.toxicon.2024.107617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Revised: 01/09/2024] [Accepted: 01/12/2024] [Indexed: 01/16/2024]
Abstract
Bungarus fasciatus also referred to as the Banded krait is a snake which possesses venom and belongs to the Elapidae family. It is widely distributed across the Indian subcontinent and South East Asian countries and is responsible for numerous snakebites in the population. B. fasciatus possesses a neurotoxic venom and envenomation by the snake results in significant morbidity and occasional morbidity in the victim if not treated appropriately. In this study, the efficacy of Indian polyvalent antivenom (Premium Serums polyvalent antivenom) was evaluated against the venom of B. fasciatus from Guwahati, Assam (India) employing the Third-generation antivenomics technique followed by identification of venom proteins from three poorly immunodepleted peaks (P5, P6 and P7) using LC-MS/MS analysis. Seven proteins were identified from the three peaks and all these venom proteins belonged to the phospholipase A2 (PLA2) superfamily. The identified PLA2 proteins were corroborated by the in vitro enzymatic activities (PLA2 and Anticoagulant activity) exhibited by the three peaks and previous reports of pathological manifestation in the envenomated victims. Neutralization of enzymatic activities by Premium Serums polyvalent antivenom was also assessed in vitro for crude venom, P5, P6 and P7 which revealed moderate to poor inhibition. Inclusion of venom proteins/peptides, which are non-immunodepleted or poorly immunodepleted, into the immunization mixture of venom used for antivenom production may help in enhancing the efficacy of the polyvalent antivenom.
Collapse
Affiliation(s)
- Amit Talukdar
- Molecular Toxinology Laboratory, Department of Molecular Biology and Biotechnology, Tezpur University, Assam, 784028, India
| | - Robin Doley
- Molecular Toxinology Laboratory, Department of Molecular Biology and Biotechnology, Tezpur University, Assam, 784028, India.
| |
Collapse
|
2
|
Sanz L, Pérez A, Quesada-Bernat S, Diniz-Sousa R, Calderón LA, Soares AM, Calvete JJ, Caldeira CAS. Venomics and antivenomics of the poorly studied Brazil's lancehead, Bothrops brazili (Hoge, 1954), from the Brazilian State of Pará. J Venom Anim Toxins Incl Trop Dis 2020; 26:e20190103. [PMID: 32362928 PMCID: PMC7179968 DOI: 10.1590/1678-9199-jvatitd-2019-0103] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 02/28/2020] [Indexed: 11/26/2022] Open
Abstract
Background: The Brazil’s lancehead, Bothrops brazili, is a poorly
studied pit viper distributed in lowlands of the equatorial rainforests of
southern Colombia, northeastern Peru, eastern Ecuador, southern and
southeastern Venezuela, Guyana, Suriname, French Guiana, Brazil, and
northern Bolivia. Few studies have been reported on toxins isolated from
venom of Ecuadorian and Brazilian B. brazili. The aim of
the present study was to elucidate the qualitative and quantitative protein
composition of B. brazili venom from Pará (Brazil), and to
carry out a comparative antivenomics assessment of the immunoreactivity of
the Brazilian antibothropic pentavalent antivenom [soro
antibotrópico (SAB) in Portuguese] against the venoms of
B. brazili and reference species, B.
jararaca. Methods: We have applied a quantitative snake venomics approach, including
reverse-phase and two-dimensional electrophoretic decomplexation of the
venom toxin arsenal, LC-ESI-MS mass profiling and peptide-centric MS/MS
proteomic analysis, to unveil the overall protein composition of B.
brazili venom from Pará (Brazil). Using third-generation
antivenomics, the specific and paraspecific immunoreactivity of the
Brazilian SAB against homologous (B. jararaca) and
heterologous (B. brazili) venoms was investigated. Results: The venom proteome of the Brazil’s lancehead (Pará) is predominantly composed
of two major and three minor acidic (19%) and two major and five minor basic
(14%) phospholipase A2 molecules; 7-11 snake venom
metalloproteinases of classes PI (21%) and PIII (6%); 10-12 serine
proteinases (14%), and 1-2 L-amino acid oxidases (6%). Other toxins,
including two cysteine-rich secretory proteins, one C-type lectin-like
molecule, one nerve growth factor, one 5'-nucleotidase, one
phosphodiesterase, one phospholipase B, and one glutaminyl cyclase molecule,
represent together less than 2.7% of the venom proteome. Third generation
antivenomics profile of the Brazilian pentabothropic antivenom showed
paraspecific immunoreactivity against all the toxin classes of B.
brazili venom, with maximal binding capacity of
132.2 mg venom/g antivenom. This figure indicates that 19% of antivenom's
F(ab')2 antibodies bind B. brazili venom
toxins. Conclusion: The proteomics outcome contribute to a deeper insight into the spectrum of
toxins present in the venom of the Brazil’s lancehead, and rationalize the
pathophysiology underlying this snake bite envenomings. The comparative
qualitative and quantitative immunorecognition profile of the Brazilian
pentabothropic antivenom toward the venom toxins of B.
brazili and B. jararaca (the reference venom
for assessing the bothropic antivenom's potency in Brazil), provides clues
about the proper use of the Brazilian antibothropic polyvalent antivenom in
the treatment of bites by the Brazil’s lancehead.
Collapse
Affiliation(s)
- Libia Sanz
- Evolutionary and Translational Venomics Laboratory, Spanish National Research Council (CSIC), Valencia, Spain
| | - Alicia Pérez
- Evolutionary and Translational Venomics Laboratory, Spanish National Research Council (CSIC), Valencia, Spain
| | - Sarai Quesada-Bernat
- Evolutionary and Translational Venomics Laboratory, Spanish National Research Council (CSIC), Valencia, Spain
| | - Rafaela Diniz-Sousa
- Center for the Study of Biomolecules Applied to Health (CEBio), Oswaldo Cruz Foundation Rondônia, Porto Velho, RO, Brazil.,Graduate Program in Experimental Biology (PGBIOEXP), Federal University of Rondônia (UNIR), Porto Velho, RO, Brazil.,São Lucas University Center (UniSL), Porto Velho, RO, Brazil
| | - Leonardo A Calderón
- Center for the Study of Biomolecules Applied to Health (CEBio), Oswaldo Cruz Foundation Rondônia, Porto Velho, RO, Brazil.,Graduate Program in Experimental Biology (PGBIOEXP), Federal University of Rondônia (UNIR), Porto Velho, RO, Brazil.,Graduate Program in Biodiversity and Biotechnology, BIONORTE Network, Porto Velho, RO, Brazil.,Aparício Carvalho University Center (FIMCA), Porto Velho, RO, Brazil
| | - Andreimar M Soares
- Center for the Study of Biomolecules Applied to Health (CEBio), Oswaldo Cruz Foundation Rondônia, Porto Velho, RO, Brazil.,Graduate Program in Experimental Biology (PGBIOEXP), Federal University of Rondônia (UNIR), Porto Velho, RO, Brazil.,São Lucas University Center (UniSL), Porto Velho, RO, Brazil.,Graduate Program in Biodiversity and Biotechnology, BIONORTE Network, Porto Velho, RO, Brazil.,National Institute of Science and Technology in Epidemiology of the Western Amazônia, (INCT-EpiAmO), Porto Velho, RO, Brazil
| | - Juan J Calvete
- Evolutionary and Translational Venomics Laboratory, Spanish National Research Council (CSIC), Valencia, Spain
| | - Cleópatra A S Caldeira
- Center for the Study of Biomolecules Applied to Health (CEBio), Oswaldo Cruz Foundation Rondônia, Porto Velho, RO, Brazil.,Graduate Program in Experimental Biology (PGBIOEXP), Federal University of Rondônia (UNIR), Porto Velho, RO, Brazil.,Graduate Program in Biodiversity and Biotechnology, BIONORTE Network, Porto Velho, RO, Brazil
| |
Collapse
|
3
|
Whiteley G, Casewell NR, Pla D, Quesada-Bernat S, Logan RAE, Bolton FMS, Wagstaff SC, Gutiérrez JM, Calvete JJ, Harrison RA. Defining the pathogenic threat of envenoming by South African shield-nosed and coral snakes (genus Aspidelaps), and revealing the likely efficacy of available antivenom. J Proteomics 2019; 198:186-98. [PMID: 30290233 DOI: 10.1016/j.jprot.2018.09.019] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 09/15/2018] [Accepted: 09/30/2018] [Indexed: 12/15/2022]
Abstract
While envenoming by the southern African shield-nosed or coral snakes (genus Aspidelaps) has caused fatalities, bites are uncommon. Consequently, this venom is not used in the mixture of snake venoms used to immunise horses for the manufacture of regional SAIMR (South African Institute for Medical Research) polyvalent antivenom. Aspidelaps species are even excluded from the manufacturer's list of venomous snakes that can be treated by this highly effective product. This leaves clinicians, albeit rarely, in a therapeutic vacuum when treating envenoming by these snakes. This is a significantly understudied small group of nocturnal snakes and little is known about their venom compositions and toxicities. Using a murine preclinical model, this study determined that the paralysing toxicity of venoms from Aspidelaps scutatus intermedius, A. lubricus cowlesi and A. l. lubricus approached that of venoms from highly neurotoxic African cobras and mambas. This finding was consistent with the cross-genus dominance of venom three-finger toxins, including numerous isoforms which showed extensive interspecific variation. Our comprehensive analysis of venom proteomes showed that the three Aspidelaps species possess highly similar venom proteomic compositions. We also revealed that the SAIMR polyvalent antivenom cross-reacted extensively in vitro with venom proteins of the three Aspidelaps. Importantly, this cross-genus venom-IgG binding translated to preclinical (in a murine model) neutralisation of A. s. intermedius venom-induced lethality by the SAIMR polyvalent antivenom, at doses comparable with those that neutralise venom from the cape cobra (Naja nivea), which the antivenom is directed against. Our results suggest a wider than anticipated clinical utility of the SAIMR polyvalent antivenom, and here we seek to inform southern African clinicians that this readily available antivenom is likely to prove effective for victims of Aspidelaps envenoming. BIOLOGICAL SIGNIFICANCE: Coral and shield-nosed snakes (genus Aspidelaps) comprise two species and several subspecies of potentially medically important venomous snakes distributed in Namibia, Botswana, Zimbabwe, Mozambique and South Africa. Documented human fatalities, although rare, have occurred from both A. lubricus and A. scutatus. However, their venom proteomes and the pathological effects of envenomings by this understudied group of nocturnal snakes remain uncharacterised. Furthermore, no commercial antivenom is made using venom from species of the genus Aspidelaps. To fill this gap, we have conducted a transcriptomics-guided comparative proteomics analysis of the venoms of the intermediate shield-nose snake (A. s. intermedius), southern coral snake (A. l. lubricus), and Cowle's shield snake (A. l. cowlesi); investigated the mechanism of action underpinning lethality by A. s. intermedius in the murine model; and assessed the in vitro immunoreactivity of the SAIMR polyvalent antivenom towards the venom toxins of A. l. lubricus and A. l. cowlesi, and the in vivo capability of this antivenom at neutralising the lethal effect of A. s. intermedius venom. Our data revealed a high degree of conservation of the global composition of the three Aspidelaps venom proteomes, all characterised by the overwhelming predominance of neurotoxic 3FTxs, which induced classical signs of systemic neurotoxicity in mice. The SAIMR polyvalent antivenom extensively binds to Aspidelaps venom toxins and neutralised, with a potency of 0.235 mg venom/mL antivenom, the lethal effect of A. s. intermedius venom. Our data suggest that the SAIMR antivenom could be a useful therapeutic tool for treating human envenomings by Aspidelaps species.
Collapse
|
4
|
Calvete JJ, Rodríguez Y, Quesada-Bernat S, Pla D. Toxin-resolved antivenomics-guided assessment of the immunorecognition landscape of antivenoms. Toxicon 2018; 148:107-122. [PMID: 29704534 DOI: 10.1016/j.toxicon.2018.04.015] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 03/26/2018] [Accepted: 04/22/2018] [Indexed: 01/23/2023]
Abstract
Snakebite envenoming represents a major issue in rural areas of tropical and subtropical regions across sub-Saharan Africa, South to Southeast Asia, Latin America and Oceania. Antivenoms constitute the only scientifically validated therapy for snakebite envenomings, provided they are safe, effective, affordable, accessible and administered appropriately. However, the lack of financial incentives in a technology that has remained relatively unchanged for more than a century, has contributed to some manufacturers leaving the market and others downscaling production or increasing the prices, leading to a decline in the availability and accessibility for these life-saving antidotes to millions of rural poor most at risk from snakebites in low income countries. The shortage of antivenoms can be significantly alleviated by optimizing the use of current antivenoms (through the assessment of their specific and paraspecific efficacy against the different medically relevant homologous and heterologous snake venoms) and by generating novel polyspecific antivenoms exhibiting broad clinical spectrum and wide geographic distribution range. Research on venoms has been continuously enhanced by advances in technology. Particularly, the last decade has witnessed the development of omics strategies for unravelling the toxin composition of venoms ("venomics") and to assess the immunorecognition profile of antivenoms ("antivenomics"). Here, we review recent developments and reflect on near future innovations that promise to revolutionize the mutually enlightening relationship between evolutionary and translational venomics.
Collapse
Affiliation(s)
- Juan J Calvete
- Evolutionary and Translational Venomics Laboratory, Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.
| | - Yania Rodríguez
- Evolutionary and Translational Venomics Laboratory, Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain
| | - Sarai Quesada-Bernat
- Evolutionary and Translational Venomics Laboratory, Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain
| | - Davinia Pla
- Evolutionary and Translational Venomics Laboratory, Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.
| |
Collapse
|